IP Management/Tech Transfer Strategies for Improved Global Health: Selected Illustrative Deals with the Private Sector.
Abstract
This presentation describes the work of DNDi and how it deals with intellectual property issues, citing examples: ASAQ (artesunate-amodiaquine for malaria), which was developed by DNDi and licensed out to sanofi-aventis; agreement with Merck to use their compound libraries and know-how to develop jointly owned intellectual property with mutually acceptable licensing arrangements; and agreement with Anacor that the company would own the rights to the products developed but could not charge royalties on their sale in public markets.
Citation
Presentation from ‘PDPs and Alternative IP Management/Tech Transfer Strategies for Improved Global Health’. Symposium held at BIO 2009, Atlanta, USA, 20 May 2009.
Links
Published 1 January 2009